Topic

Articles

 Budget battle threatens efforts to bolster Europe’s pharma strategy.

Health Policy Funding, Hopes at Odds in EU 

Andrew Hood, is Partner, Regulatory and Trade, and Cliodhna McDonough is Director, Regulatory, at 

Andrew Hood and Cliodhna McDonough look at the key issues necessary to support business and the community in developing a long-term and sustainable response to the challenges highlighted by COVID-19.

EU Medical Device Supply Chains and Trade Agreements: The COVID-19 Response

Pandemic sparks call for European manufacturing renaissance.

Is Drug Production Heading Back to Europe From Abroad?

Industry prospects at mercy of public discourse, policy shifts.

The Specter of Compulsory Licensing Haunts Vaccine Debate

Pandemic fallout could spell fundamental business and policy shifts.

A New, Less Friendly Normal Looms for European Drugmakers

Medical devices manufacturers and pharma companies alike should review their compliance strategies as the EU Medical Device Regulation Date of Application approaches.

Getting through the EU MDR and IVDR Whirlwind: Steps to Compliance

The collection of source plasma for new therapies igniting debate.

Blood Feud Divides Europe Over Plasma Shortfalls

Cliodhna McDonough is a life sciences lawyer at Fieldfisher.

The Medicines and Medical Devices Bill was recently introduced to the UK House of Commons. Does it provide the confidence that the UK is still a leading country for life sciences? Cliodhna McDonough reports.

Does the UK Medicines and Medical Devices Bill Provide Post-Brexit Certainty?

New OECD study doesn’t shed much light on the effectiveness of managed entry agreements for drug access.

Unlocking the Black Box of Pharma Pricing in Europe

Remco Munnik is Associate Director at Iperion, a globally-operating life sciences consultancy firm which is paving the way to digital healthcare, and as such strongly committed to contributing to the actual implementation of the ISO IDMP standards. www.iperion.comRemco.munnik@iperion.com 

Goals for IDMP in Europe must not be diluted in 2020, if standardized medicinal product data is to be of tangible real-world benefit, says Remco Munnik.

Europe